tetrandrine

Small moleculeexperimental

Tetrandrine, isolated from the root of Stephania tetrandra S Moore, is a traditional Chinese clinical agent for silicosis, autoimmune disorders, inflammatory pulmonary diseases, cardiovascular diseases and hypertension. Tetrandrine is a potent MDR-reversing agent and is an ABCB1/ABCC1 inhibitor. Tetrandrine (CBT-1) is being developed by CBA Pharma, as an adjunctive therapy to chemotherapy in various cancer types with multiple drug resistance (MDR), including acute myelogenous leukemia , Breast, Non-Hodgkin’s Lymphoma, Hodgkin’s disease, Non-Small Cell Lung Cancer, Multiple Myeloma, Gallbladder, Pancreatic, Gastrointestinal Tract, Small Cell Lung Cancer, Bladder, Head & Neck, and Sarcoma. — NCATS

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Mar 5, 2020 (NCT04308317)

Timeline

No events for the selected filters.

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COC1=CC=C2C[C@@H]3N(C)CCC4=C3C(OC5=CC6=C(CCN(C)[C@H]6CC7=CC=C(OC1=C2)C=C7)C=C5OC)=C(OC)C(OC)=C4
Mol. weight
622.7499 g/mol

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05697029Phase 4Dec 31, 2023Peking University
NCT05245448N/AFeb 22, 2022Peking University
NCT04308317Phase 4Mar 5, 2020Henan Provincal People's Hospital
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Peking UniversityAcademic/Hospital2222022
Henan Provincal People's HospitalAcademic/Hospital1112020
2 organizations
Page 1 / 1